<DOC>
	<DOCNO>NCT02900729</DOCNO>
	<brief_summary>Hypertension represent significant global public health problem , contribute vascular renal morbidity , cardiovascular mortality , economic burden . For mostly asymptomatic disease , huge challenge maintain good adherence longtime persistence drug use adequately control . Even , significant proportion patient develop resistant hypertension . In recent year , renal denervation argue effective mean address blood pressure problem several non-Chinese clinical trial . The technique deliver low level radiofrequency energy renal artery wall target sympathetic nervous system modulate blood pressure . Shanghai WiseGain Medical Devices Co. , LTD develop WiseGo Catheter System , irrigated radiofrequency ablation Catheter . With Catheter , expect improve blood pressure status among patient resistant hypertension fail polypharmacy . The purpose randomize control trial obtain assessment efficacy safety WiseGo renal denervation technique presence three standard antihypertensive medication Chinese patient .</brief_summary>
	<brief_title>Randomized Controlled Trial Renal Denervation Resistant Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Antihypertensive Agents</mesh_term>
	<mesh_term>Hydrochlorothiazide</mesh_term>
	<mesh_term>Losartan</mesh_term>
	<mesh_term>Amlodipine</mesh_term>
	<criteria>1 . Subject primary hypertension 24hour ambulatory systolic blood pressure ≥ 135 mmHg office systolic blood pressure ≥ 140 mmHg /office diastolic blood pressure ≥ 90 mmHg 4week standardised triple therapy . 2 . Subject ≥ 18 &lt; 80 year old time randomization . 3 . Subject agree study procedure perform , willing provide write informed consent participate clinical study . 1 . Subject acute serious systemic infection . 2 . Subject history renal artery interventional therapy . 3 . Subject lack suitable renal artery anatomy percutaneous renal sympathetic nerve radiofrequency ablation surgery , include limited presence serious aorta renalartery tortuosity renalartery stenosis . 4 . Subject experienced myocardial infarction , unstable angina pectoris , syncope , cerebrovascular accident within three month screen period , widespread atherosclerosis , document intravascular thrombosis . 5 . Subject aortic dissection aneurysm . 6 . Subject primary pulmonary hypertension . 7 . Subject estimate glomerular filtration rate le 40 mL/min/1.73m² accord Modification Diet Renal Disease formula . 8 . Subject definite diagnose coronary heart disease require beta blocker 9 . Subject Class III IV heart failure leave ventricular ejection fraction &lt; 45 % . 10 . Subject atrial fibrillation . 11 . Subject significant bleeding tendency blood system disease ( ) . 12 . Subject malignancy endstage disease ( ) . 13 . Subject secondary hypertension . 14 . Subject type 1 diabetes mellitus . 15 . Subject condition inappropriate participation investigator 's discretion . 16 . Subject medical ethic concern investigator 's discretion , presence 24hour Ambulatory Blood Pressure Monitoring average systolic blood pressure ≥ 170 mmHg 4week standardised triple therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>